- GLP-1 drugs can cause up to 10% lean muscle mass loss — comparable to a decade or more of aging — according to an analysis published by the American Diabetes Association, raising serious frailty and safety concerns.
- Researchers say resistance training can significantly slow muscle loss, but many prescribers are not informing patients; one researcher called for labels to read “must be taken with resistance training.”
- People on GLP-1s regain weight four times faster than those who lose weight through lifestyle changes, and regained weight is predominantly fat — compounding the metabolic risk of muscle loss.
- Medicare will begin covering GLP-1s for eligible seniors in July, raising particular concern among doctors given the heightened frailty and injury risks muscle loss poses for those over 50.
What Happened?
As 13 million Americans now take GLP-1 drugs such as Ozempic, Mounjaro, and Zepbound, a growing body of research is documenting a serious side effect that receives little attention at the point of prescription: rapid and significant loss of lean muscle mass. An analysis published by the American Diabetes Association found GLP-1 users can lose up to 10% of their lean tissue — equivalent to a decade or more of aging — over a short period. Patients and doctors describe consequent frailty, instability, fatigue, and trouble with basic physical tasks. Research shows resistance training can substantially slow the muscle loss, but many prescribers give no guidance on exercise, leaving patients to self-educate via online forums.
Why It Matters?
The scale of GLP-1 adoption makes this a population-level health concern. Losing significant muscle mass accelerates metabolism slowdown — which helps explain why patients who stop GLP-1s regain weight four times faster than those who lost weight through diet and exercise, with regained weight being predominantly fat. The cycle creates a dependency dynamic the drugs were not designed to address. For older Americans, the risks are heightened: Medicare begins covering GLP-1s in July, bringing the drugs to a population where muscle loss most directly drives falls, fractures, and loss of independence. Women appear more vulnerable to adverse reactions including muscle loss than men, according to a 2025 Italian hospital study.
What’s Next?
Drug companies including Boehringer Ingelheim are developing next-generation GLP-1 formulations designed to preserve or build muscle while driving fat loss — a direct response to the frailty concern. Eli Lilly halted a similar trial last September. Scientists are calling for expanded clinical trials across broader demographics, noting that existing research has focused almost exclusively on patients with obesity or Type 2 diabetes — not the growing population using GLP-1s for lifestyle weight loss. Regulators and prescribers face pressure to update guidance, particularly as telehealth companies prescribe the drugs without in-person assessments that would flag muscle mass and mobility risks.
Source: The Wall Street Journal
